Squarepoint’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-13,193
| Closed | -$2.27M | – | 3687 |
|
|
2021
Q3 | $2.27M | Buy |
13,193
+11,451
| +657% | +$1.5M | 0.01% | 1143 |
|
|
2021
Q2 | $219K | Sell |
1,742
-3,753
| -68% | -$473K | ﹤0.01% | 2758 |
|
|
2021
Q1 | $745K | Sell |
5,495
-4,604
| -46% | -$595K | ﹤0.01% | 1738 |
|
|
2020
Q4 | $1.29M | Buy |
10,099
+843
| +9% | +$98.8K | 0.01% | 1173 |
|
|
2020
Q3 | $1.04M | Buy |
9,256
+1,968
| +27% | +$196K | 0.01% | 982 |
|
|
2020
Q2 | $694K | Sell |
7,288
-14,978
| -67% | -$1.44M | 0.01% | 1134 |
|
|
2020
Q1 | $2M | Buy |
22,266
+17,021
| +325% | +$1.32M | 0.05% | 437 |
|
|
2019
Q4 | $278K | Sell |
5,245
-4,406
| -46% | -$201K | ﹤0.01% | 2078 |
|
|
2019
Q3 | $381K | Sell |
9,651
-20,275
| -68% | -$880K | ﹤0.01% | 1764 |
|
|
2019
Q2 | $1.23M | Buy |
29,926
+4,247
| +17% | +$176K | 0.01% | 1141 |
|
|
2019
Q1 | $1.2M | Buy |
+25,679
| New | +$1.13M | 0.01% | 1012 |
|
|
2018
Q4 | – | Sell |
-17,651
| Closed | -$1.01M | – | 2353 |
|
|
2018
Q3 | $1.01M | Sell |
17,651
-8,549
| -33% | -$420K | 0.01% | 982 |
|
|
2018
Q2 | $1.27M | Buy |
26,200
+17,070
| +187% | +$622K | 0.02% | 802 |
|
|
2018
Q1 | $357K | Buy |
9,130
+3,931
| +76% | +$167K | 0.01% | 1236 |
|
|
2017
Q4 | $221K | Sell |
5,199
-3,282
| -39% | -$123K | ﹤0.01% | 1746 |
|
|
2017
Q3 | $317K | Buy |
+8,481
| New | +$294K | 0.01% | 1157 |
|
|
2017
Q2 | – | Sell |
-13,579
| Closed | -$359K | – | 1913 |
|
|
2017
Q1 | $359K | Sell |
13,579
-5,073
| -27% | -$134K | 0.01% | 1008 |
|
|
2016
Q4 | $476K | Buy |
+18,652
| New | +$591K | 0.02% | 861 |
|
|
2016
Q1 | – | Sell |
-5,200
| Closed | -$254K | – | 1538 |
|
|
2015
Q4 | $254K | Buy |
+5,200
| New | +$187K | 0.03% | 875 |
|
Squarepoint's XLRN Position: Q4 2021 in Review
Squarepoint sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 13,193 shares — an estimated $2.27M sold.
Squarepoint first reported a position in XLRN in Q4 2015 and held it in 19 quarters. The position peaked at $2.27M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Squarepoint reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Squarepoint sold 13,193 Acceleron Pharma shares in Q4 2021, an estimated $2.27M.
- Squarepoint first reported a position in Acceleron Pharma in Q4 2015 and held it in 19 quarters.
- Squarepoint's Acceleron Pharma position peaked at $2.27M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.